BioLineRx Ltd. (BLRX:NASDAQ) closed at $1.52 on November 10, 2026, down 3.80% on the day. The stock trades 61.5% below its 52-week high of $3.95 and 4.8% above its 52-week low of $1.45. Over the past year, it lost 54.1%. BioLineRx Ltd. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, BLRX closed higher on 109 days (43%). Its best day was April 28, 2026 (+17.94%) and its worst was March 23, 2026 (-12.45%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 3 times.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company's development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Find more stocks like BLRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.